Claritev Corporation (CTEV), formerly MultiPlan Corporation, provides data-analytics and technology-enabled cost-management, payment, and revenue-integrity solutions to the U.S. healthcare industry. Five sell-side price targets form the basis of the central target: Barclays at $40, Piper Sandler at $73, Wells Fargo at $30, Canaccord Genuity at $43, and Citi at $45. The average of these five is $46.20, rounded to a $46 central target, in line with the figure reported by S&P Global.
The $30-to-$73 spread is unusually wide and signals a genuine split in opinion. Bulls, led by Piper Sandler's $73 target, emphasize accelerating revenue growth, strong bookings, and improving margins. More cautious voices, including Wells Fargo's Hold-rated $30 target, focus on the company's elevated debt load and negative GAAP earnings per share (EPS). The overall stance is constructive, with most firms rating the stock Buy or equivalent, but the dispersion means the average should not be read as a precise forecast.
Shares of CTEV trade near $24, well below their 52-week high of roughly $73 and above the 52-week low near $11.50. To reach $46, the stock would need to appreciate approximately 90%, a very large move by any standard. A path toward that level would most likely require sustained mid-to-high single-digit revenue growth, continued deleveraging of the balance sheet, and progress returning the Payment & Revenue Integrity segment to growth in 2027, alongside a re-rating of the stock's valuation multiple.
Claritev reported third-quarter 2026 revenue of $268.3 million, up 9.1% year over year, its sixth consecutive quarter of growth and its highest quarterly revenue in 17 quarters. Trailing twelve-month revenue surpassed $1 billion for the first time since early 2023. Management raised full-year 2026 revenue guidance to roughly $1.04 billion and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) to $625-$630 million, while pointing to at least $1.1 billion of revenue in 2027. Annualized contract value bookings are growing sharply, and the company is diversifying beyond payer clients. These trends underpin the bullish side of the analyst range.
The primary obstacle is the balance sheet. Net leverage stood near 7.7x at quarter-end, and the company continues to report GAAP net losses, with a Q3 2026 net loss of $61.8 million and GAAP EPS of negative $3.64. Adjusted EBITDA margin declined to 60.4% from 63.1% a year earlier, and free cash flow remained negative in the quarter due to elevated capital expenditures. The Payment & Revenue Integrity segment is running behind internal plans as clients shift toward Claims Intelligence solutions. High leverage, ongoing losses, and margin compression could all cap valuation and keep the stock well short of the average target.
The stock's $11.50-to-$73 52-week range shows substantial volatility. At roughly $24, CTEV sits in the lower half of that range, with the $46 target positioned roughly midway between the current price and the prior high. Round-number levels near $25 and $30 could act as intermediate resistance, while the area near $20 and the prior low provide potential support zones. The long-term structure remains a wide, choppy trading range rather than a clean uptrend.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may differ and no timeframe was uniformly disclosed. Investors should watch quarterly earnings and guidance updates, any changes to leverage or refinancing plans, bookings and new-client announcements, and analyst target revisions, which have been frequent and substantial for this name. The wide target range means revisions in either direction could materially shift the consensus view.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review allows. Explore the AI Daily Buy/Sell Signals to see how automated intelligence can support your market research.
The $46 central target represents the average of five analyst price targets and implies a roughly 90% advance from current levels near $24. That is a very large move, and the $30-to-$73 spread shows analysts themselves disagree sharply on the path ahead. The bull case rests on reaccelerating revenue, record bookings, and raised guidance, while the bear case centers on 7.7x leverage, persistent GAAP losses, and margin erosion. Whether CTEV can reach $46 will likely depend most on continued top-line momentum and meaningful balance-sheet improvement. No outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CTEV has been loosely correlated with COMP. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CTEV jumps, then COMP could also see price increases.
| Ticker / NAME | Correlation To CTEV | 1D Price Change % | ||
|---|---|---|---|---|
| CTEV | 100% | +19.46% | ||
| COMP - CTEV | 36% Loosely correlated | -7.41% | ||
| CLSK - CTEV | 36% Loosely correlated | -4.92% | ||
| RIOT - CTEV | 34% Loosely correlated | +2.38% | ||
| COIN - CTEV | 32% Poorly correlated | -2.92% | ||
| TGL - CTEV | 30% Poorly correlated | -1.69% | ||
More | ||||
| Ticker / NAME | Correlation To CTEV | 1D Price Change % |
|---|---|---|
| CTEV | 100% | +19.46% |
| Services to the Health Industry industry (42 stocks) | 4% Poorly correlated | -0.05% |
| Health Services industry (239 stocks) | -0% Poorly correlated | -1.13% |